Moleculin Biotech, Inc. (MBRX) Social Stream
Moleculin Biotech Inc (MBRX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Moleculin Biotech Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 32 weeks, MBRX's average price target has gone down $2.33.
Over the past 51 weeks, MBRX's average upside potential has been 552.98%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MBRX Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 21 months, MBRX's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Moleculin Biotech Inc's upside potential (average analyst target price relative to current price) is higher than 197.84% of them.
- To contextualize these metrics, consider that out of all US stocks, Moleculin Biotech Inc's variance in analysts' estimates is lower than -85.51% of them.
- Moleculin Biotech Inc's number of analysts covering the stock is greater than 25.2% of Healthcare stocks.
- In terms of how Moleculin Biotech Inc fares relative to stocks in the micro market cap category, note that its average analyst price target is greater than 144.72% of that group.
Make investment decisions regarding MBRX using the data that counts. Try POWR Ratings for free.